Methods for making ultrasound contrast agents

US10220104B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10220104-B2
Application numberUS-201815940932-A
CountryUS
Kind codeB2
Filing dateMar 29, 2018
Priority dateJul 6, 2016
Publication dateMar 5, 2019
Grant dateMar 5, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for preparing a phospholipid suspension useful for preparing an ultrasound contrast agent comprising combining DPPA, DPPC and MPEG5000-DPPE, in propylene glycol to form a phospholipid solution, the MPEG5000-DPPE selected as having a calcium concentration of less than 115 parts per million (ppm), wherein the phospholipid solution has a calcium concentration of less than 0.7 ppm, and combining the phospholipid solution with an aqueous solution to form a phospholipid suspension. 2. The method of claim 1 , wherein DPPA, DPPC and MPEG-5000-DPPE are present in a mole % ratio of 10 to 82 to 8 (10:82:8). 3. The method of claim 1 , wherein calcium concentration of DPPA is less than 780 ppm, calcium concentration of DPPC is less than 90 ppm, and the calcium concentration of propylene glycol is less than 0.7 ppm. 4. The method of claim 2 , wherein calcium concentration of DPPA is less than 780 ppm, calcium concentration of DPPC is less than 90 ppm, and calcium concentration of propylene glycol is less than 0.7 ppm. 5. The method of claim 1 , further comprising placing the phospholipid suspension in a container. 6. The method of claim 5 , further comprising introducing a perfluorocarbon gas into the container. 7. The method of claim 5 , wherein the container comprises perfluorocarbon gas. 8. The method of claim 6 , wherein the perfluorocarbon gas is perfluoropropane gas. 9. The method of claim 7 , wherein the perfluorocarbon gas is perfluoropropane gas. 10. A method for preparing a phospholipid suspension useful for preparing an ultrasound contrast agent comprising combining DPPA, DPPC and MPEG5000-DPPE in propylene glycol, in a methanol and toluene free and methyl t-butyl ether free condition, to form a phospholipid solution, wherein MPEG5000-DPPE has a calcium concentration of less than 115 parts per million (ppm), and wherein the phospholipid solution has a calcium concentration of less than 0.7 ppm, and combining the phospholipid solution with an aqueous solution to form a phospholipid suspension. 11. The method of claim 10 , wherein DPPA, DPPC and MPEG-5000-DPPE are present in a mole % ratio of 10 to 82 to 8 (10:82:8). 12. The method of claim 10 , wherein calcium concentration of DPPA is less than 780 ppm, calcium concentration of DPPC is less than 90 ppm, and the calcium concentration of propylene glycol is less than 0.7 ppm. 13. The method of claim 11 , wherein calcium concentration of DPPA is less than 780 ppm, calcium concentration of DPPC is less than 90 ppm, and calcium concentration of propylene glycol is less than 0.7 ppm. 14. The method of claim 10 , further comprising placing the phospholipid suspension in a container. 15. The method of claim 14 , further comprising introducing a perfluorocarbon gas into the container. 16. The method of claim 14 , wherein the container comprises perfluorocarbon gas. 17. The method of claim 15 , wherein the perfluorocarbon gas is perfluoropropane gas. 18. The method of claim 16 , wherein the perfluorocarbon gas is perfluoropropane gas.

Assignees

Inventors

Classifications

  • A61K49/227Primary

    Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric · CPC title

  • A61K49/223Primary

    Microbubbles, hollow microspheres, free gas bubbles, gas microspheres · CPC title

  • Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title

  • Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels · CPC title

  • Preparation processes; Proliposomes · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10220104B2 cover?
Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Who is the assignee on this patent?
Lantheus Medical Imaging Inc
What technology area does this patent fall under?
Primary CPC classification A61K49/227. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 11 related publications on this page (citations in our corpus or others sharing the same primary CPC).